-
公开(公告)号：WO2019034774A1
公开(公告)日：2019-02-21
申请号：PCT/EP2018/072319
申请日：2018-08-17
Applicant: ISTITUTO EUROPEO DI ONCOLOGIA (IEO) S.R.L.
Inventor： VARASI, Mario , CAPPA, Anna , VIANELLO, Paola , MORETTI, Loris , SARTORI, Luca , MERCURIO, Ciro
IPC: C07D495/04 , A61P31/00 , A61P3/00 , A61P35/00 , A61K31/4045
Abstract: The present application relates to compounds of formula (I), wherein A, R, R 1 , and R 2 are as defined in the specification, pharmaceutical compositions containing such compounds and to their use in therapy.
-
2.发明申请USE OF THE EXPRESSION OF SPECIFIC GENES FOR THE PROGNOSIS OF PATIENTS WITH TRIPLE NEGATIVE BREAST CANCER 审中-公开特异性基因表达在预测三阴性乳腺癌患者中的应用
公开(公告)号：WO2018002385A1
公开(公告)日：2018-01-04
申请号：PCT/EP2017/066533
申请日：2017-07-03
Inventor： STEFAN, Michiels , BAYAR, Mohamed Amine , ANDRE, Fabrice , CRISCITIELLO, Carmen , CURIGLIANO, Giuseppe
IPC: C12Q1/68
Abstract: The present invention relates to the use of the value of the expression of at least one gene selected from the group comprising: GBP1 gene, HLF gene, CXCL13 gene and SULT1E1 gene, for the estimation of prognosis of distant relapse-free survival or overall survival of a patient with triple negative breast cancer (TNBC) having received a neoadjuvant chemotherapy (NACT).
Abstract translation: 本发明涉及选自包括GBP1基因，HLF基因，CXCL13基因和SULT1E1基因的组中的至少一种基因的表达值用于评估预后的用途 患有接受新辅助化疗（NACT）的三阴性乳腺癌（TNBC）的患者的远期无复发存活或总体存活。
-
3.发明申请METHODS AND KITS COMPRISING GENE SIGNATURES FOR STRATIFYING BREAST CANCER PATIENTS 审中-公开方法和试剂盒包含基因签名分类乳腺癌患者
公开(公告)号：WO2017220492A1
公开(公告)日：2017-12-28
申请号：PCT/EP2017/064937
申请日：2017-06-19
Applicant: ISTITUTO EUROPEO DI ONCOLOGIA (IEO) , FONDAZIONE FIRC PER I'ONCOLOGIA MOLECOLARE (IFOM) , UNIVERSITA DEGLI STUDI DI MILANO (UNIVERSITY OF MILAN)
Inventor： DI FIORE, Pier Paolo , PECE, Salvatore , VECCHI, Manuela , CONFALONIERI, Stefano
IPC: C12Q1/68
CPC classification number: C12Q1/6886 , C12Q2600/106 , C12Q2600/112 , C12Q2600/118 , C12Q2600/158 , C12Q2600/16 , C12Q2600/166 , G16B5/00 , G16B40/00
Abstract: The present invention relates to refined prognostic clinical tools, methods, and kits for the evaluation of risk and treatment of distant recurrence in ER+/HER2- breast cancer patients.
Abstract translation: 本发明涉及用于评估ER + / HER2-乳腺癌患者中远处复发的风险和治疗的改进的预后临床工具，方法和试剂盒。
-
-
Search Results
3
records
(took 0.068 seconds)
